Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
27 hedge funds and large institutions have $16.8M invested in Northwest Biotherapeutics, Inc. Common stock in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
88% more capital invested
Capital invested by funds: $8.95M → $16.8M (+$7.88M)
35% more funds holding
Funds holding: 20 → 27 (+7)
16% more call options, than puts
Call options by funds: $135K | Put options by funds: $116K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$7.57M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.42M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$375K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$221K |
| 5 |
CL
Croft-Leominster
Baltimore,
Maryland
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$1.67M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$124K |
| 3 |
Jane Street
New York
|
-$87K |
| 4 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$14.7K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$1.15K |
NWBO Hedge Fund Activity: Q3 2013 in Review
27 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2013, worth a combined $16.8M — up 88% from $8.95M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NWBO positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $7.57M. The largest seller was Whitebox Advisors, cutting an estimated $1.67M.
- 27 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2013, up from 20 in Q2 2013.
- Funds reported $16.8M of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2013, up 88% quarter-over-quarter.
- 9 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2013 and 2 closed out, a net change of +7 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2013 was Franklin Resources, an estimated $7.57M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2013 was Whitebox Advisors, an estimated $1.67M sold.
Based on aggregated 13F filings for Q3 2013.